South Korea's Enzychem To Make Cadila's COVID-19 Shot
NDTV
As part of the deal, Cadila will transfer the DNA vaccine technology to Enzychem, which will make and sell the vaccine, ZyCoV-D, within its territory under the Cadila trademark.
South Korea's Enzychem Lifesciences would make at least 80 million doses of India's homegrown DNA COVID-19 vaccine from Cadila Healthcare, the domestic drugmaker said on Wednesday.
As part of the deal, Cadila will transfer the DNA vaccine technology to Enzychem, which will make and sell the vaccine, ZyCoV-D, within its territory under the Cadila trademark. Cadila will get license fees and royalty payments, the company said in a filing https://bit.ly/3HZz3a2 to stock exchanges.
"(The DNA) technology allows vaccines to be produced at affordable costs in record times, and DNA vaccines are considerably stable," said Ki Young Sohn, chairman of Enzychem Lifesciences.
"ZyCoV-D is administered without needles and can be deployed more readily, especially in resource-poor populations."
